ISO 42001 for Drug Discovery and Clinical Trial AI

Pharma has been governing software for decades. GAMP 5 tells you how to validate a computerized system. 21 CFR Part 11 tells you how to control electronic records and signatures. ICH Q9 tells you how to manage quality risk. What none of that machinery was built to answer is a much newer question: what happens when the system making a decision wasn't programmed with fixed rules, but learned its behavior from data, and keeps behaving differently as that data shifts underneath it?

That's the gap ISO/IEC 42001:2023 is built to close, and it's why I think pharma companies running AI in discovery or clinical operations need to stop treating "AI governance" as a slide in a slide deck and start treating it as a management system with its own clauses, its own risk assessment discipline, and its own audit trail. I've written elsewhere about how ISO 42001 fits into a GxP environment; this piece goes narrower, into the two AI use cases that carry the most regulatory and reputational weight: drug discovery models and clinical trial algorithms.

Why Drug Discovery AI and Clinical Trial AI Are Different Governance Problems

It's tempting to treat "AI in pharma" as one category. It isn't. A generative chemistry model proposing novel compounds and a patient-recruitment algorithm screening trial candidates fail in completely different ways, answer to different regulators, and put different people at risk when they go wrong.

The point of the table isn't the table. It's that a single AI policy document covering "AI use at [company]" will be too vague to do real work in either domain. ISO 42001 clause 4.1 requires you to determine issues relevant to your AI management system's purpose, and clause 4.2 requires you to identify the needs of interested parties — for discovery AI that's mostly internal (R&D leadership, IP counsel); for clinical trial AI it expands to participants, IRBs, and regulators. Scope the management system for both, but don't govern them identically.

Where ISO 42001 Sits Alongside Existing Pharma Regulation

ISO 42001 doesn't replace anything pharma already does. It sits on top of and connects the AI-specific gaps that GxP, GCP, and record-keeping rules were never designed to cover.

FDA's own May 2023 discussion paper, "Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products," was explicit that the agency doesn't yet have a single AI-specific regulatory framework for drug development — it's building expectations use case by use case. That's exactly the environment where a certifiable management system standard has the most value: it gives you a defensible answer to "how do you govern this" before the regulator finishes writing the specific rule.

What ISO 42001 Actually Requires — Mapped to Pharma AI

Skip the marketing version of ISO 42001 and look at the clauses that create real work.

Clause 6.1.2 — AI risk assessment. You have to identify risks associated with the development, provision, or use of AI systems, using criteria you've defined and can defend. For a discovery model, that includes the risk of a false negative burying a viable compound and the risk of a false positive consuming six months of medicinal chemistry time. For a clinical trial model, it includes the risk of an adaptive randomization algorithm systematically underenrolling a demographic subgroup.

Clause 6.1.3 — AI system impact assessment. This is the clause pharma teams underestimate. It asks you to assess the impact AI systems can have on individuals and groups — not just on the business. A recruitment algorithm that inadvertently screens out patients from lower-income zip codes because it weights insurance-verification speed isn't a data science problem; it's an impact the standard requires you to have assessed in writing before the system goes live.

Annex A.5 — Impact assessment. Operationalizes 6.1.3 into a control: a documented process, not a one-time memo. For clinical trial AI in particular, this is where I'd expect an auditor to spend the most time, because it's the clause closest to informed consent and participant welfare.

Annex A.6 — AI system life cycle. Requires controls across the full life cycle: design, development, verification, deployment, operation, and decommissioning. In drug discovery, this means the same model version discipline you already apply to a validated LIMS or ELN system, extended to training runs, hyperparameter changes, and retraining triggers.

Annex A.7 — Data for AI systems. Requires documented processes for data acquisition, quality, and provenance. If your discovery model was trained on a compound library with undocumented lineage, or your trial-matching algorithm pulls from an EHR feed with unclear consent scope, this is the control that fails first — and it's usually the one that surfaces during an internal audit before it surfaces in front of a regulator.

Clause 9.1 — Monitoring, measurement, analysis, and evaluation. Requires ongoing measurement of AI system performance, not a validation event followed by silence. This is where GAMP 5's periodic review concept and ISO 42001's monitoring requirement should be run as the same activity, not two parallel compliance exercises.

Applying This to Drug Discovery AI

Three areas carry the most governance weight in discovery, in my experience advising on AI management systems: generative chemistry, target identification, and in silico toxicity prediction.

Generative and predictive chemistry models. The control gap I see most often is version-to-decision traceability. If a generative model proposes a scaffold that advances to synthesis, you need to be able to reconstruct, months later, which model version, which training data snapshot, and which confidence threshold produced that recommendation. Annex A.6 life cycle controls exist precisely to make that reconstruction possible.

Target identification models. These carry a subtler risk: the model's training data reflects the biology that's already been studied, which means it will systematically underweight novel or understudied targets. That's not a bug to fix; it's a limitation to document under clause 6.1.2 so the humans making go/no-go decisions know what the model can't see.

In silico toxicity and ADMET prediction. These models sit closest to safety, which means they deserve the tightest impact assessment under Annex A.5, even though the "impact" at this stage is still internal — a missed toxicity signal here doesn't reach a patient, but it can reach a first-in-human trial if downstream teams treat the model's output as more certain than it is. The control that matters is disclosure of confidence intervals and known failure modes to every downstream decision-maker, not just a validation report that lives in a QA file.

Applying This to Clinical Trial AI

Clinical trial AI is where ISO 42001's people-centered clauses stop being theoretical, because the "interested parties" in clause 4.2 are trial participants.

Patient recruitment and eligibility screening algorithms. These are the highest-scrutiny use case right now, and for good reason: an algorithm that screens candidates against eligibility criteria can encode bias from its training data (which patients historically enrolled, which sites historically recruited well) into which patients get offered a trial today. The Annex A.5 impact assessment needs to explicitly test for disparate impact across the demographic groups the trial's own inclusion criteria are meant to represent, and that assessment needs to happen before first patient enrolled, not after a monitoring visit flags an imbalance.

Adaptive trial design and response-adaptive randomization. These algorithms change trial behavior — dosing arms, randomization ratios — based on accumulating data. ICH E6(R3)'s risk-based quality management approach already asks you to identify what's "critical to trial" and monitor it; ISO 42001's clause 9.1 monitoring requirement is the mechanism that keeps that identification alive across the life of the trial rather than only at protocol design.

AI-assisted endpoint adjudication and imaging analysis. When an algorithm classifies a scan, flags a lab value, or scores a clinical outcome, its error rate becomes part of the trial's data integrity story under 21 CFR Part 11. The control I'd push hardest here is a documented human-override rate: how often adjudicators overrule the algorithm, and whether that rate is itself monitored as a quality indicator. A model that's never overruled either is superb or isn't being seriously reviewed, and you want your quality system to know which.

Digital biomarkers and wearable-derived endpoints. These introduce a data provenance question Annex A.7 was written for: was the training data for the biomarker algorithm collected under conditions representative of the trial population, or optimized on a healthier, more compliant cohort that skews performance once deployed at scale?

Building the Statement of Applicability for This Scope

If discovery and clinical AI sit inside the same certification scope, your Statement of Applicability needs to justify control selections separately for each, not blend them into one generic rationale. A control like A.7.4 (quality of data for AI systems) will be justified very differently for a proprietary compound library than for a multi-site EHR feed pulling in identifiable patient records — same control number, different evidence, different risk owner. I've laid out the broader logic for selecting and justifying controls in the SoA guide; the pharma-specific wrinkle is that your SoA will need to cross-reference your existing GxP validation documentation rather than duplicate it, or you'll end up maintaining two versions of the same evidence that drift apart within a year.

Where Pharma AI Programs Actually Get Stuck

The most common gap isn't the risk assessment — teams are usually decent at identifying risks once asked. It's clause 6.1.4, treatment of AI risks: turning an identified risk into an assigned owner, a control, and a residual risk decision that someone with authority actually signs. I've reviewed programs with excellent risk registers and no record of who accepted the residual risk on a toxicity model's known blind spots. That's the finding that costs you a certification cycle, not the finding that costs you a redraft.

The second gap is retraining governance. A model retrained on new data is, functionally, a new model. Few pharma AI programs have a documented threshold for what triggers revalidation versus what counts as routine tuning — and without that threshold, Annex A.6 life cycle controls exist on paper but not in practice.

FAQ

Does ISO 42001 replace GAMP 5 for AI systems used in GxP environments? No. GAMP 5 validates that a computerized system performs as intended within a risk-based framework; ISO 42001 governs the AI-specific risks GAMP 5 wasn't designed to address, like training data provenance and model drift. Run them together, cross-referenced, not as competing frameworks.

Is ISO 42001 certification required by FDA or EMA for AI used in drug development? No regulator currently mandates ISO 42001 certification for pharmaceutical AI. FDA's January 2025 draft guidance describes a risk-based credibility assessment for AI models supporting regulatory decisions, and a certified AI management system is one of the strongest ways to demonstrate the governance maturity that assessment expects, but certification itself isn't a submission requirement.

How does ISO 42001 apply differently to a clinical trial recruitment algorithm versus a drug discovery model? Clinical trial algorithms trigger the standard's impact-assessment clauses (6.1.3, Annex A.5) because they affect real participants and interact with informed consent and IRB oversight. Drug discovery models carry more weight under the life-cycle and data-governance clauses (Annex A.6, A.7) because the primary risk is internal — wasted resources or missed signals — rather than direct harm to a person.

What's the first control gap pharma companies should check before pursuing certification? Data provenance under Annex A.7. If you can't document where training data for a discovery or trial-support model came from, and under what consent or licensing terms, no amount of downstream risk-assessment paperwork will hold up under audit.

Does the EU AI Act apply to pharmaceutical AI even if the company is US-based? It can. Regulation (EU) 2024/1689 applies to AI systems placed on the EU market or whose output is used in the EU, regardless of where the provider is headquartered — a US-based sponsor running an EU trial site or seeking EMA approval should assume the Act's obligations apply to the AI systems involved in that work.

If you're scoping an AI management system across discovery and clinical operations and want a second set of eyes on where the risk actually concentrates, our pharma-specific implementation work starts with exactly this kind of use-case mapping before a single control gets selected.

Last updated: 2026-08-20